"10.1371_journal.pone.0080166","plos one","2013-11-11T00:00:00Z","Bianca Begh√©; Alessia Verduri; Barbara Bottazzi; Mariarita Stendardo; Alessandro Fucili; Sara Balduzzi; Chiara Leuzzi; Alberto Papi; Alberto Mantovani; Leonardo M Fabbri; Claudio Ceconi; Piera Boschetto","Department of Medical and Surgical Sciences, University of Modena & Reggio Emilia, Modena, Italy; Laboratory of Research in Immunology and Inflammation, Humanitas Clinical and Research Center, Rozzano, and Department of Translational Medicine, University of Milan, Milan, Italy; Department of Medical Sciences, University of Ferrara, Ferrara, Italy","Conceived and designed the experiments: B. Begh√® CC AM LMF PB AP. Performed the experiments: B. Begh√® AV B. Bottazzi MS AF CL PB. Analyzed the data: B. Begh√® AV SB B. Bottazzi LMF PB. Wrote the manuscript: B. Begh√®  AV B. Bottazzi LMF PB.","The authors have reported the following conflicts of interest: AP is on the Chiesi, AstraZeneca, and Zambon Boards; has received consultancy fees from Chiesi, AstraZeneca, GlaxoSmithKline, and Zambon; has received research support from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Merck Sharp & Dome; and has received lecture fees from Chiesi, AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Merck Sharp & Dome, Menarini, and Novartis. Dr LMF received payment for consultancy from: Almirall, Boehringer Ingelheim, Chiesi Farmaceutici, Euromediform,  GlaxoSmithKline, Merck Sharp & Dhome, Mundipharma International, Novartis, Nycomed, Parexel, Pearl Therapeutics, Sigma-Tau, Sterna, Peer Voice Europe, OM Pharma Sa, TEVA; payment for lectures, advisory boards or travel expenses reimbursements from: AstraZeneca, Dey Pharma, Gr√ºnenthal GmbH, Mundipharma International, Novartis, Sigma-Tau, Roche, Genetech Inc, Elevation Pharmaceutical, Ferrer Group; his institution received grants from AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Menarini Industrie Farmaceutiche, Merck Sharp & Dhome, Novartis, Nycomed, Roche, SigmaTau, Pfizer, Italian Ministry for University and Research, Italian Ministry of Health. Dr B. Begh√® received payment for lectures or travel expense reimbursements from AstraZeneca, Menarini, Chiesi Farmaceutici, Takeda Pharmaceuticals International GmbH; and payment for development of educational presentations from Takeda Pharmaceuticals International GmbH. Dr. AM and Dr. B. Bottazzi are inventors on patents related to the therapeutic and diagnostic use of PTX3. Their institution receives royalties related to marketing of PTX3-related reagents. Dr. AF received payment for lectures, advisory boards or travel expenses reimbursements from AstraZeneca, Menarini, Chiesi Farmaceutici, Takeda Pharmaceuticals, Boehringer Ingelheim, Merck, Merck Sharp & Dohme, SigmaTau, Pfizer, Novartis. The patent names and numbers that we refer to in the manuscript are:
- US 2004/0137544 A1. PTX3 as an early prognostic indicator of cardiovascular and cerebrovascular pathologies.
- WO 2005/106494 A2. Monoclonal antibodies, hybridomans, improved method for determining the protein PTX3 and kit for said determination.
- US 8,003,109 B2. Pharmaceutical compositions containing the long pentraxin PTX3.
This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. The authors alone are responsible for the writing and the content of this paper.","2013","11","Bianca Begh√©","BB√",12,TRUE,1,1,1,1,TRUE,TRUE,TRUE,8,"2;4;5;7;8;9;10;11",TRUE
